by admin | Dec 6, 2016 | Stem Cell News
NEW YORK, Dec. 6, 2016 /PRNewswire-USNewswire/ — The combination of two new drugs that harness the body’s immune system is safe and effective, destroying most cancer cells in 64 percent of patients with recurrent Hodgkin lymphoma, according to the results...
by admin | Dec 5, 2016 | Stem Cell News
WASHINGTON (AP) — A bipartisan bill to speed government drug approvals and bolster biomedical research cleared its last procedural hurdle in the Senate on Monday in an emotional moment for Vice President Joe Biden. The overwhelming 85-13 vote puts the measure on track...
by admin | Dec 5, 2016 | Stem Cell News
Peter Lynch Chart of JUNO The company says that the previous treatment of these patients with ibrutinib, AbbVie ‘s ( ABBV ) Imbruvica, was unsuccessful and the observations collected “from studies of the translational product, JCAR014, are being applied to...
by admin | Dec 5, 2016 | Stem Cell News
19,219.08 48.66 (0.25%) Bellicum Pharmaceuticals Announces GoCAR-T and GoTCR Preclinical Presentations at the American Society of Hematology 2016 Annual Meeting Share SAN DIEGO–(BUSINESS WIRE)– Bellicum Pharmaceuticals, Inc. ( BLCM ), a clinical stage...
by admin | Dec 5, 2016 | Stem Cell News
Tweet Share HAIFA, Israel, Dec 5 (Reuters) – Israeli biotech company Bonus Biogroup’s lab-grown, semi-liquid bone graft was successfully injected into the jaws of 11 people to repair bone loss in an early stage clinical trial, it said on Monday. The...
by admin | Dec 5, 2016 | Stem Cell News
83 The rates of treatment-related adverse events (AEs) with Opdivo plus Yervoy remained similar to those previously reported. Treatment related AEs of any grade were 84% and 74% for the Q12W and Q6W combination cohorts, respectively. The Grade 3/4 AEs were 42% and 31%...
